Wang G, et al. - Researchers undertook this study to systematically explore efficacy and safety of the proof-of-concept of the ICS (inhaled corticosteroid) plus fast-onset-acting β₂-agonist (FABA) regimen in a single inhaler as reliever therapy across children and adults with intermittent and mild persistent asthma. Findings suggested that for treating intermittent or mild asthma, ICS/FABA as a symptom-driven therapy may be a promising alternative regimen.